Bagai Shaun

CEO Bagai Shaun buys 24,300 shares of RenovoRx (RNXT) on 2026-03-20; CLUSTER pattern: 3 insiders buying within 14 days.

Bagai Shaun, CEO, acquired 24,300 shares on 2026-03-20, raising his holdings from 289,057 shares to 313,357 shares (+8.4%). This purchase is part of a cluster pattern in which 2 other insiders also bought within the past 14 days, suggesting coordinated conviction at this price level. RenovoRx remains unprofitable (net income of $-2.9M in the latest full fiscal year) with minimal quarterly revenue of $266.0K, making this a high-risk biotech story. Bagai's prior trades at RNXT show mixed timing outcomes: 3 of 5 prior buys were well-timed at the 90-day mark, including a +53.9% 90-day return on an April 2025 purchase and +40.1% and +31.9% returns on consecutive August 2025 buys, though recent December 2025 purchases returned only +13.2% and +19.7% respectively over 30 days. The stock has risen 18.3% over the past 30 days and 20.6% over 90 days but remains -23.9% from its 52-week high of $1.42, creating a technical backdrop where the insider's persistence merits attention given the company's losses.

CEO Bagai Shaun buys 5,000 shares of RNXT at $0.90; stock down 41.6% from 52-week high but up 13.1% in 30 days.

Bagai Shaun, Chief Executive Officer of RenovoRx Inc., purchased 5,000 shares at $0.90 on 2025-12-18, increasing his holdings to 340,040 shares. The purchase occurs in a context of significant volatility: the stock is down 41.6% from its 52-week high of $1.54 but has rebounded 13.1% over the prior 30 days. Critically, the company remains unprofitable (full-year net income was negative, with the latest quarter showing net income of $-2.9M against revenue of $266.0K), presenting a fundamental risk environment. Across his prior trades at RNXT, Bagai has shown mixed timing: 2 of 4 measurable prior buys were well-timed at the 90-day mark (30-day returns of +22.0% and +27.7% extended to +53.9% and +56.6% at 90 days), but the two most recent completed transactions (2025-08-25 and 2025-08-22) showed deteriorating 90-day outcomes (-12.5% and -18.0% respectively despite strong 30-day returns). This latest purchase warrants investor attention to whether it represents opportunistic accumulation at a depressed point in a volatile cycle or conviction in turnaround prospects at a company with substantial operational headwinds.

CEO Shaun Bagai buys 5,000 RNXT shares at $0.85; stock down -39.6% from 52-week high but up +27.0% in 30 days.

Shaun Bagai, Chief Executive Officer of RenovoRx, purchased 5,000 shares at $0.85 on 2025-12-17, increasing his holdings to 335,040 shares. This transaction occurs as the stock trades $0.93, within its 52-week range of $0.73–$1.54, down -39.6% from its peak but up +27.0% over the past 30 days—suggesting near-term momentum into the purchase. Examining Bagai's prior trading at RNXT: of his 4 measurable same-ticker buys, 2 achieved positive 90-day returns (+53.9% and +56.6%), while 2 resulted in negative 90-day returns (-12.5% and -18.0%), indicating mixed timing outcomes at this specific ticker. The company remains unprofitable with net income of $-2.9M on quarterly revenue of $266.0K and a market cap of $34.1M, which underscores that this buy occurs in the context of a pre-revenue-stage biotech facing significant financial headwinds. The purchase is modest in absolute terms ($4.3K) relative to his existing position, yet the pattern of his repeated buying (5 prior trades at RNXT) alongside ongoing losses warrants attention to whether the CEO's conviction in the science outweighs current financial metrics.

CEO Bagai buys 10,000 shares at avg $0.93, extending 100% 90-day win rate across 4 prior RNXT buys despite stock down 40.3% from 52-week high.

Shaun Bagai, Chief Executive Officer, executed 2 separate purchases totaling 10,000 shares for $9,296.50, acquiring at $0.95 on 2025-08-22 and $0.91 on 2025-08-25, in a $33.7M market-cap company with $-2.9M net income. The current stock price of $0.92 sits 40.3% below the 52-week high and down 27.6% in the last 30 days, yet his prior trades at this ticker show a perfect timing pattern: all 4 prior buys at RNXT have generated positive 90-day returns (ranging +15.2% to +63.9%), with a 100% win rate at the 90-day mark. His cross-ticker track record mirrors this: 4 prior buys averaged +27.8% at 30 days and +47.4% at 90 days, also with 100% win rate. The purchases increase his holdings from 320,040 shares to 330,040 shares (+3.1%), executed while the company remains unprofitable with minimal quarterly revenue of $422,000.00. This filing is notable because the insider is adding to a position in a distressed equity while extending a demonstrated pattern of well-timed buy execution specifically at this same ticker.

CEO Shaun Bagai buys 7,500 shares at $0.91; cluster pattern with 3 other insiders in past 14 days amid -33.1% 52-week decline.

CEO Shaun Bagai purchased 7,500 shares at $0.91 on 2025-04-15, increasing holdings to 320,040 shares—a continuation of buying activity that began just one week prior, with this being the third purchase in 9 days. Most notably, 3 other insiders also bought within the past 14 days, forming a cluster pattern that suggests aligned conviction at depressed valuations near the 52-week low. The company is unprofitable with negative net income of $-2,471,000.00 over its most recent full fiscal year, and the stock has declined -27.0% over 90 days and sits -33.1% from its 52-week high of $1.54. Bagai's cross-ticker track record shows a 100% win rate on buys with average 90-day returns of +15.2%, but his same-ticker history at RNXT contains only one completed outcome (buy on 2024-01-26 with +15.2% 90-day return), limiting confidence in his prior ability to time this specific ticker; the simultaneous buying by multiple insiders in a distressed, unprofitable company warrants investor scrutiny.

CEO Shaun Bagai bought 10,000 shares of RNXT at $0.83; stock down 48.7% from 52-week high, company unprofitable, 3 other insiders bought within 14 days

Shaun Bagai, Chief Executive Officer, purchased 10,000 shares at $0.83 on 2025-04-09, bringing his holdings to 312,540 shares (+3.3% vs prior position). The timing follows a sharp decline: RNXT has fallen 48.7% from its 52-week high and dropped 40.6% over 90 days, though Bagai's prior RNXT buy on 2024-01-26 generated a +15.2% 90-day return. The company faces fundamental headwinds, reporting net income of $-2.5M over its most recent full fiscal year. Notably, this purchase occurs as part of a cluster pattern with 3 other insiders buying within the past 14 days, suggesting coordinated confidence from the leadership team despite deteriorating financial performance and significant recent stock depreciation.

CEO Bagai Shaun bought 10,000 shares of RNXT at $0.83; stock down 48.0% from 52-week high amid cluster buying and unprofitability.

Shaun Bagai, Chief Executive Officer, purchased 10,000 shares at $0.83 on 2025-04-07, increasing his holdings from 292.5K to 302.5K shares. The transaction occurs amid significant stock weakness: the current price of $0.80 is 48.0% below the 52-week high of $1.54, and the stock has declined 39.4% over the past 90 days. The company reported a negative net income of $-2.5M for its most recent full fiscal year. Notably, three other insiders also purchased shares within the past 14 days, forming a cluster buy pattern, while Bagai's prior buy at this ticker (2024-01-26) showed strong 90-day performance (+15.2%), though his cross-ticker track record is based on a single prior transaction. The convergence of management buying pressure during a significant drawdown, combined with simultaneous purchases by other insiders, suggests coordination in response to market conditions, though the company's unprofitable state warrants investor scrutiny of whether such buying reflects conviction or represents a temporary response to depressed valuations.